PT  - JOURNAL ARTICLE
AU  - Aleksandra Natalia Strojna
AU  - Beyhan Ataseven
AU  - Florian Heitz
AU  - Nicole Concin
AU  - Malak Moubarak
AU  - Timo Westermann
AU  - Sabrina Kaiser
AU  - Nina Pauly
AU  - Timoleon Dagres
AU  - Vasileios Vrentas
AU  - Andreas du Bois
AU  - Alexander Traut
AU  - Philipp Harter
TI  - 2022-RA-1008-ESGO The impact of cytoreductive surgery in FIGO IV and recurrent endometrial cancer
AID  - 10.1136/ijgc-2022-ESGO.277
DP  - 2022 Oct 01
TA  - International Journal of Gynecologic Cancer
PG  - A129--A129
VI  - 32
IP  - Suppl 2
4099  - http://ijgc.bmj.com/content/32/Suppl_2/A129.2.short
4100  - http://ijgc.bmj.com/content/32/Suppl_2/A129.2.full
SO  - Int J Gynecol Cancer2022 Oct 01; 32
AB  - Introduction/Background The aim of the study was to assess the oncological outcomes of cytoreductive surgery in FIGO IV and recurrent endometrial cancer.Methodology This is a retrospective, observational, single-center cohort study including patients with endometrial cancer FIGO IV stage disease undergoing primary cytoreductive surgery and recurrent endometrial cancer treated with secondary cytoreductive surgery between January 1999 and April 2022.Results 115 patients were included in the present study. In the 53 patients with primary FIGO IV disease complete macroscopic resection was achieved in 42/53 (79.2%) cases. Median OS in these patients was 35 months and median PFS was 15 months. Sixty-two patients had cytoreductive surgery for relapsed endometrial cancer and complete macroscopic resection was achieved in 82.2%. Median OS in this population was 28 months and median PFS was 8.2 months. Patients with complete macroscopic resection showed longer progression-free survival (PFS) and overall survival (OS) compared to those with residual disease (PFS: 15.1 vs 12.9 months; p=0,189; OS: 32.4 vs 17 months; p=0,130). Median OS was 44.6 months (95 % CI 24,6- 64,6 months) in endometrioid subtype (72/115 pts) and 27.4 months (95 %CI 7.2–47.6 months) in other histotypes (p=0.114). Major complications (>Clavien Dindo IIIB) were noted in 10/115 pts (8.7%), mortality rate was 0.9%.Conclusion Complete macroscopic resection is feasible in selected patients with FIGO IV and relapsed endometrial cancer with an acceptable morbidity, and seemed to be related to superior outcome. However, its impact on prognosis should be further evaluated.